Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antisense oligonucleotides | 5846 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Olezarsen is an antisense oligonucleotide (ASO) directed against apolipoprotein C-III (APOC3) mRNA. Olezarsen binds to APOC3 mRNA and reduces production of APOC3 protein through degradation of the target mRNA.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 19, 2024 | FDA | Ionis Pharmaceuticals | |
| Sept. 17, 2025 | EMA | Swedish Orphan Biovitrum AB |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| FDA CS | M0025055 | Oligonucleotides, Antisense |
| MeSH PA | D057847 | Lipid Regulating Agents |
| FDA EPC | N0000191626 | Antisense Oligonucleotide |
| FDA EPC | N0000194144 | APOC-III-directed RNA Interaction |
| FDA PE | N0000194154 | Increased RNA Degradation |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Familial chylomicronemia syndrome | indication | 402786009 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) | TRYNGOLZA (AUTOINJECTOR) | IONIS PHARMS INC | N218614 | Dec. 19, 2024 | RX | SOLUTION | SUBCUTANEOUS | 9157082 | April 27, 2032 | USE IN REDUCING TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) |
| EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) | TRYNGOLZA (AUTOINJECTOR) | IONIS PHARMS INC | N218614 | Dec. 19, 2024 | RX | SOLUTION | SUBCUTANEOUS | 9593333 | Feb. 14, 2034 | USE IN REDUCING TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) |
| EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) | TRYNGOLZA (AUTOINJECTOR) | IONIS PHARMS INC | N218614 | Dec. 19, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12509684 | May 1, 2034 | USE IN REDUCING TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) |
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) | TRYNGOLZA (AUTOINJECTOR) | IONIS PHARMS INC | N218614 | Dec. 19, 2024 | RX | SOLUTION | SUBCUTANEOUS | Dec. 19, 2031 | ADJUNCT TO DIET TO REDUCE TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) |
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| apolipoprotein C-III (apoC-III) mRNA | RNA | ANTISENSE INHIBITOR | IC50 | 6.74 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 2097587-83-0 | SECONDARY_CAS_RN |
| CHEMBL4650438 | ChEMBL_ID |
| C000731151 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4044091 | VANDF |
| C5556529 | UMLSCUI |
| CHEBI:758324 | CHEBI |
| CHEMBL4650263 | ChEMBL_ID |
| 11801 | INN_ID |
| 2298451-31-5 | SECONDARY_CAS_RN |
| 13658 | IUPHAR_LIGAND_ID |
| S3RS2SA30L | UNII |
| 2701417 | RXNORM |
| D13023 | KEGG_DRUG |
| 43610 | MMSL |
| d10239 | MMSL |
| 019949 | NDDF |
| 019950 | NDDF |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TRYNGOLZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71860-101 | INJECTION, SOLUTION | 80 mg | SUBCUTANEOUS | NDA | 31 sections |
| TRYNGOLZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71860-102 | INJECTION, SOLUTION | 50 mg | SUBCUTANEOUS | NDA | 31 sections |